Floatz logo
Floatz Rating
B58/100
Confidence
Indicative
v0.2
Sponsor
Genentech, Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05867121CT.gov
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
—Completed———
NCT05773092CT.gov
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
—Active Not Recruiting———
NCT05529355CT.gov
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
—Unknown———
NCT04465968CT.gov
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
—Not Yet Recruiting———
NCT03700333CT.gov
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC
—Unknown———
NCT03457337CT.gov
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
—Unknown———
NCT03129256CT.gov
An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer
—Completed———
NCT02855125CT.gov
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
—Completed———
NCT02631460CT.gov
S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Non-Small Cell Lung Carcinoma

AssetSponsorPhaseRating
S-1 (this asset)Genentech, Inc.P3B · 58
IcotinibThe First Affiliated Hospital of Guangzhou Medical UniversityP4BBB
NecitumumabJonsson Comprehensive Cancer CenterP3BBB
EndostatinHenan Cancer HospitalP4BBB
ZorifertinibAlpha Biopharma (Jiangsu) Co., Ltd.P2/3BBB
d-0316Betta Pharmaceuticals Co., Ltd.P2/3BBB
GlumetinibShanghai JMT-Bio Inc.P3BBB
OnartuzumabHoffmann-La RocheP3BBB
Vinorelbine DitartrateIntergroupe Francophone de Cancerologie ThoraciqueP4BB

+42 more in the Non-Small Cell Lung Carcinoma cohort

Other indications for S-1

IndicationSponsorPhaseRating
Malignant Pancreatic Neoplasm—P4BB · 66
Pancreatic Neoplasm—P4B · 63
Colorectal Cancer—P3B · 63

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. S-1 in Non-Small Cell Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/s-1-non-small-cell-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →